BACKGROUND: @entity810 ( @entity810 ) is common and often leads to significant morbidity and/or @entity204 . The development of @entity810 , or complications associated with it, may be due to use of certain medications in at-risk @entity1 experiencing an intercurrent illness. Implicated drugs include diuretics, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/direct renin inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), @entity2449 and @entity5736 . Expert consensus opinion (and clinical guidelines) recommend considering discontinuation of diuretics, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/direct renin inhibitors, NSAIDs, @entity2449 and @entity5736 in the event of an intercurrent illness to prevent @entity810 onset or reduce severity or complications. However, the evidence base for these recommendations is very limited. This systematic review aims to address the available evidence for the temporary discontinuation of diuretics, ACE inhibitors, angiotensin receptor blockers, direct renin inhibitors, non-steroidal anti-inflammatories and @entity2449 and @entity5736 for those at risk of @entity810 or with newly diagnosed @entity810 . METHODS/DESIGN: Randomised controlled trials; non-randomised trials; cohort studies; case-control studies; interrupted time series studies; and before-and-after studies featuring adults aged 18 and over in any setting currently taking diuretics, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/direct renin inhibitors, NSAIDs and @entity2449 ; experiencing an intercurrent illness; or undergoing a radiological/surgical procedure (planned or unplanned) will be searched for. Relevant trial registers and systematic review databases will be searched. Systematic reviews will be assessed for methodological quality using the ROBIS tool, trials will be assessed using the Cochrane risk of bias tool, and observational studies will be assessed using the ACROBAT-NRS tool. If sufficient studies assessing similar populations, study type, settings and outcomes are found, then a formal meta-analysis will be performed to estimate summary measures of effect. If not, a narrative synthesis will be adopted. DISCUSSION: This review will synthesise evidence for the efficacy of discontinuing diuretics, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/direct renin inhibitors, NSAIDs, @entity2449 or @entity5736 to prevent or delay onset of @entity810 or associated complications. Results will provide guidance on efficacy and safety of this strategy and potentially help to develop an intervention to test the best mechanism of guiding medication discontinuation in at-risk populations. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42015023210.

The risks and benefits of XXXX temporarily discontinuing medications in the event of an intercurrent illness: a systematic review protocol.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity5736 :: ('D013453', 'Chemical') :: ['sulfonylureas'] @entity810 :: ('MESH:D058186', 'Disease') :: ['AKI', 'Acute kidney injury'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity2449 :: ('MESH:D008687', 'Chemical') :: ['metformin']
@entity1 :: (9606,Species) :: ['patients']
